Accessibility Menu
 
Galera Therapeutics logo

Galera Therapeutics

(OTC) GRTX

Current Price$0.04
Market Cap$3.14M
Since IPO (2019)-100%
5 Year-99%
1 Year+60%
1 Month+1%

Galera Therapeutics Financials at a Glance

Market Cap

$3.14M

Revenue (TTM)

$0.00

Net Income (TTM)

$149.05M

EPS (TTM)

$1.98

P/E Ratio

0.02

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$0.04

Volume

5,753

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.02 - $0.06

GRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Galera Therapeutics

Industry

Biotechnology

Employees

3

CEO

John Mel Sorensen, MD

Headquarters

Malvern, PA 19355, US

GRTX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

-92%

Return on Assets

21%

Earnings Yield

50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.14M

Shares Outstanding

75.58M

Volume

5.75K

Short Interest

0.00%

Avg. Volume

53.98K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$6.04M

EBITDA

$6.04M

Operating Cash Flow

$6.05M

Capital Expenditure

$0.00

Free Cash Flow

$6.05M

Cash & ST Invst.

$6.38M

Total Debt

$0.00

Galera Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$3.14M

N/A

Market Cap/Employee

$1.05M

N/A

Employees

3

N/A

Net Income

$153.10M

+3204.9%

EBITDA

$1.51M

+70.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$6.38M

+104.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

20.71%

N/A

Return on Invested Capital

-92.23%

N/A

Free Cash Flow

$2.24M

+4.3%

Operating Cash Flow

$2.24M

+4.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VCNXVaccinex, Inc.
$1.00+0.00%
ANTCFAion Therapeutic Inc.
$0.00+0.00%
HESGHealth Sciences Group, Inc.
$0.00+0.00%
STMMStemcell Holdings, Inc.
$0.06-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$62.38+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.61+0.02%
CRWVCoreWeave
$102.00+0.11%
NOKNokia
$9.46-0.01%

Questions About GRTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.